Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1,1,1-Trifluoro-3-acetamido-4-phenyl butan-2-one (N-acetyl-L-phenylalanyl trifluoromethyl ketone) is a synthetic small molecule with the molecular formula C12H12F3NO2 and a molecular weight of approximately 259.22 g/mol[1][2][6]. It is structurally related to phenylalanine derivatives and contains a trifluoromethyl ketone moiety. This compound has been studied primarily as an experimental inhibitor of serine proteases such as chymotrypsin[7], where it acts by binding to the active site and inhibiting enzymatic activity. There are no approved therapeutic indications or clinical trials for this compound in humans; its use is limited to biochemical research as a tool compound for studying protease function[2][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1,1,1-trifluoro-3-acetamido-4-phenyl butan-2-one.